Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05176015
Other study ID # MP-CIBSSSBSL-2021-03
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 15, 2022
Est. completion date October 31, 2024

Study information

Verified date April 2024
Source CHU de Quebec-Universite Laval
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study is perfomed to validate and document faisability of the use of Frenzel lens and the use of a diagnostic algorithm for the assessment of a special sign (nystagmus) observe in the eyes of patients consulting in the emergency department (ED) for an acute episode of vertigo/dizziness/imbalance.


Description:

This pilot study is a randomized controlled trial 2 by 2 design to allocated randomly the Frenzel lens and the diagnostic algorithm. There is no use of sham lens. The usual care opposed to the diagnostic algorithm will be questioned only on the perception of nystagmus by the clinician and the use of repositioning particles technique. The only blinding will be the patients about the use of the algorithm and the outcomes assessor about the use or not of Frenzel lens and the use or not of the diagnostic algorithm.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date October 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - New episode of acute vertigo/dizziness/imbalance occuring during the 28 last days - Must be able to consent. Exclusion Criteria: - No traumatic context before symptoms onset - No intoxication context - Glycemia = 3,0 mmol/L - Only one participation is permitted - Not able to speak adequately in French or English. - Reachable for 3 month follow-up

Study Design


Intervention

Device:
Frenzel Lens
pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
Diagnostic Test:
Diagnostic Algorithm
A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous. The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test. Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers. Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score

Locations

Country Name City State
Canada Centre Hospitalier d'Amqui Amqui Quebec
Canada Hopital Notre-Dame-de-Fatima La Pocatiere Quebec
Canada Centre Hospitalier de Matane Matane Quebec
Canada Centre Hospitalier de Montmagny Montmagny Quebec
Canada Hopital St-Georges St-Georges Quebec

Sponsors (1)

Lead Sponsor Collaborator
CHU de Quebec-Universite Laval

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Nystagmus detection per participant During eye examination, nystagmus will be characterized according to prominent direction of the fast phase (patients' left, patients' right, up, down, rotational),with their clinical setting or trigger. Overall rate of nystagmus detection by participant. (Rate of typical nystagmus for benign paroxysmal positional vertigo in the Dix-Hallpike maneuver or Supine Head Roll Test. Rate of nystagmus detection in the initial physical exam) Day 0
Secondary Emergency Department Length of stay Time spent at the emergency department from triage to time of departure for hospital admission or for home discharge assessed up to 48 hours Day 0, from triage time to Emergency Department departure (admission or home discharge)
Secondary Rate of neuro-imaging per participant Any imaging to investigate acute intra-cerebral lesion and/or the neck/brain vascular. anomaly : computed tomography imaging; computed tomography angiogram; magnetic resonance angiography; magnetic resonance imaging, vascular neck ultrasound imaging. From day 0 to 12 weeks
Secondary Rate of acute stroke per participant Any acute stroke, hemorrhagic or ischemic, diagnosed by neuro-imaging: computed tomography or magnetic resonance imaging From day 0 to 12 weeks
Secondary Rate of symptomatic central lesion per participant Any central lesion diagnosed by computed tomography or magnetic resonance imaging that may be related to the initial presentation of vertigo/dizziness/imbalance From day 0 to 12 weeks
Secondary Rate of specialised consultations for vertigo/dizziness/imbalance per participant Any specialised consultations (neurology, ear nose and throat (ENT), cardiology or similar) to investigate the acute vertigo/dizziness/imbalance with the final diagnosis. Sumarisation of final diagnosis. From day 0 to 12 weeks
Secondary Rate of acute vertigo/dizziness/imbalance related hospitalisation per participant Admission to hospital directly related to vertigo/dizziness/imbalance may be immediate to initial visit or delayed. From day 0 to 12 weeks
Secondary Rate of subsequent Emergency Department Visit for Vertigo/dizziness/imbalance per participant Return visit to the emergency department for vertigo/dizziness/imbalance as chief complaint. From day 0 t0 12 weeks
Secondary Rate of New Atrial Fibrillation Atrial fibrillation detected by the initial visit electrocardiogram or by long-term cardiac rhythm monitoring (Holter or loop recorder). From day 0 to 12 weeks
Secondary Rate of New Stroke at 12 weeks A stroke free status will be assessed by a validated questionnaire by telephone at tree months and all specialised consultations and neuroimaging will be reviewed for acute stroke diagnosis, At 12 weeks
Secondary Rate of the use of Particles Repositioning Technique Once Paroxysmal Positional Vertigo diagnosis is being diagnosed with the Dix-Hallpike test or with the Supine Head Roll test, the use of particles repositioning technique, Epley or Gufoni maneuvers, will be noted with their immediate impact on acute vertigo. Day 0
Secondary Rate of Emergency Department Visit Return for Benign Paroxysmal Positional Vertigo according to Typical Nystagmus Rate of Emergency Department Visit Return for Benign Paroxysmal Positional Vertigo according to Typical Nystagmus: direction, duration From day 0 to 12 weeks
Secondary Initial managment self appreciation of patient presenting in the ED for an acute episode of vertigo/dizziness/imbalance Simple question answered on a likert scale at the end of the ED encounter. 0% worst, 100% best appreciation. Day 0
Secondary Adverse Events Combination of stroke, death, neurosurgery, intervenional neuroradiology, thrombolytic therapy From day 0 to 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Completed NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Completed NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Completed NCT03633422 - Evaluation of Stroke Patient Screening
Completed NCT04088578 - VNS-supplemented Motor Retraining After Stroke N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Not yet recruiting NCT05534360 - Tenecteplase Treatment in Ischemic Stroke Registry
Withdrawn NCT05786170 - ERILs Und SNILs Unter SOC N/A
Not yet recruiting NCT04105322 - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Completed NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS)
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT05760326 - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients